Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
We are seeking to out-license our product portfolio to territories where we do not have sales and marketing operations More
Cellophil™ is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
New Active Ingredient + Innovative Drug Delivery System = Business Success More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
The XGEL ™ polymer technology is available for licensing and replaces the need to use animal-derived gelatine in pharmaceutical and healthcare products More
This ORS effervescent tablet has been developed according to the latest guidelines of the WHO. We are looking for partners in Europe and in other areas to commercialize the ORS effervescent tablets More
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints. More
MT204, in preclinical development stage, neutralizes both IL-2 as well as IL-2 bound to CD25 conferring a broader anti-inflammatory activity over current therapies targeting IL-2 pathway for the treatment of inflammatory and autoimmune diseases. More
Your selection
- Therapeutic target
- Respiratory del
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adult respiratory distress syndrome
- Allergy, respiratory
- Asthma
- Asthma, bronchospasm
- Bronchitis
- Chest disorder (other)
- Chlamydia pneumoniae
- Chronic obstructive pulmonary disease
- Cough
- Cystic fibrosis
- Dysplasia, bronchopulmonary
- Emphysema
- Granulomatous lung disease sarcoidosis
- Idiopathic respiratory distress syndrome
- Meconium aspiration syndrome
- Nasal disorder (other)
- Obstructive airway disease
- Pneumonia
- Pneumonocystis carinii lung infection
- Pseudomonas lung infection
- Respiratory disorder (other)
- Respiratory syncytial virus
- Respiratory tract infections
- Rhinitis
- Rhinovirus (common cold)
- Sinusitis
- Sleep apnea
- Throat disorder (other)
- Tuberculosis
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us